Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Sézary syndrome
clinical practices statement
cutaneous T-cell lymphoma
management
mycosis fungoides
Journal
The Australasian journal of dermatology
ISSN: 1440-0960
Titre abrégé: Australas J Dermatol
Pays: Australia
ID NLM: 0135232
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
16
06
2020
revised:
16
08
2020
accepted:
17
08
2020
pubmed:
29
12
2020
medline:
28
10
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Primary cutaneous lymphomas represent a heterogeneous group of T- and B-cell lymphomas with distinct clinical presentations, histopathologic features, treatment approaches and outcomes. The cutaneous T-cell lymphomas, which include mycosis fungoides and Sézary syndrome, account for the majority of the cutaneous lymphomas. This Clinical Practice Statement is reflective of the current clinical practice in Australia. An expanded form of the Clinical Practice Statement (and updates), along with helpful patient resources and access to support groups, can be found at the following (http://www.australasianlymphomaalliance.org.au).
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e8-e18Informations de copyright
© 2020 The Australasian College of Dermatologists.
Références
Willemze R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-14.
Willemze R. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
Querfeld, C.P.H.M.R.S.T.Cutaneous T-cell lymphomas: Mycosis Fungoides and Sezary Syndrome. A Guide for the Practicing Oncologist.
Quaglino P, Prince Hm, Cowan R et al. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Study (PROCLIPI study). Br. J. Dermatol. 2020 Jun 1. doi: 10.1111/bjd.19252. Epub ahead of print.
Scarisbrick JJ, Prince HM, Vermeer MH et al. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J. Clin. Oncol. 2015; 33: 3766-73.
Gilson D, Whittaker SJ, Child FJ et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br. J. Dermatol. 2019; 180: 496-526.
Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat. Rep. 1979; 63: 725-8.
Agar NS et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J. Clin. Oncol. 2010; 28: 4730-9.
Benton EC, Crichton S, Talpur R et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur. J. Cancer 1990; 2013: 2859-68.
Diamandidou E, Cohen PR, Kuzrock R. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J. Am. Acad. Dermatol. 1999; 40(6 Pt 1): 914-24.
Diamandidou E, Colome-Grimmer M, Fayad L et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998; 92: 1150-9.
Scarisbrick JJ, Whittaker S, Evans AV et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001; 97: 624-30.
Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood 2019; 134: 1072-83.
Booher S, McCann SA, Tawa MC. Cutaneous T-Cell Lymphoma: Mycosis Fungoides/Sézary Syndrome, Part 2. J. Dermatol. Nurses' Assoc. 2011; 3: 75-83.
Gutman AB, Kligman AM, Sciacca J et al. Soak and Smear: A Standard Technique Revisited. Arch. Dermatol. 2005; 141: 1556-9.
Querfeld C, R.S.T.K.T.M.Cutaneous T-cell lymphoma (Mycosis fungoides and Sézary’s syndrome), in Conn’s Current Therapy, Rakel Re BET Editor. 2006, Elsevier/Saunders: Philadelphia. 902-6.
Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch. Dermatol. 1998; 134: 949-4.
Ling TC, Clayton TH, Crawley J et al. British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015. The British Journal of Dermatology 2016; 174: 24-55.
Dogra S, Mahajan R. Phototherapy for mycosis fungoides. Indian J. Dermatol. Venereol. Leprol. 2015; 81: 124.
Querfeld C. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch. Dermatol. 2005; 141: 305-11.
Roenigk HH, Kuzel TM, Skoutelis AP et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J. Invest. Dermatol. 1990; 95(6 Suppl): 198S-205S.
Oğuz O, Engin B, Aydemir EH. The influence of psoralen + ultraviolet A treatment on the duration of remission and prognosis in mycosis fungoides. J. Eur. Acad. Dermatol. Venereol. JEADV 2003; 17: 483-5.
Herrmann JJ, Roenigk HH, Hurria A et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J. Am. Acad. Dermatol. 1995; 33(2 Pt 1): 234-42.
Gathers RC, Scherschun L, Malick F et al. Narrowband UVB phototherapy for early-stage mycosis fungoides. J. Am. Acad. Dermatol. 2002; 47: 191-7.
Clark C, Dawe RS, Evans AT et al. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch. Dermatol. 2000; 136: 748-52.
Ramsay DL et al. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch. Dermatol. 1992; 128: 931-3.
Milstein HJ, Vonderheid EC, Van Scott EJ et al. Home ultraviolet phototherapy of early mycosis fungoides: preliminary observations. J. Am. Acad. Dermatol. 1982; 6: 355-62.
Ponte P, Serrão V, Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J. Eur. Acad. Dermatol. Venereol.: JEADV 2010; 24: 716-21.
Resnik KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients. J. Am. Acad. Dermatol. 1993; 29: 73-77.
Pavlotsky F, Barzilai A, Kasem R et al. UVB in the management of early stage mycosis fungoides. J. Eur. Acad. Dermatol. Venereol.: JEADV 2006; 20: 565-72.
Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J. Am. Acad. Dermatol. 2001; 44: 755-61.
Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N. Engl. J. Med. 1997; 336: 1041-5.
Hüsken AC, Tsianakas A, Hensen P et al. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad. Dermatol. Venereol.: JEADV 2012; 26: 71-8.
Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81.
Kuzel TM, Roenigk HH, Samuelson E et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J. Clin. Oncol. 1995; 13: 257-63.
Neelis KJ, Schimmel EC, Vermeer MH et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int. J. Radiat. Oncol. Biol. Phys. 2009; 74: 154-8.
Cotter GW, Baglan RT, Wasserman TH et al. Palliative radiation treatment of cutaneous mycosis fungoides-a dose response. Int J Radiat Oncol Biol Phys 1983; 9: 1477-80.
Esposito L, Piccinno R, Marchese L, Berti E. Results of radiotherapy in minimal stage mycosis fungoides: a reappraisal after ten years. G Ital Dermatol Venereol 2018; 155: 483-86.
Jones GW, Tadros A, Hodson DI et al. Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY. Int. J. Radiat. Oncol. Biol. Phys. 1994; 28: 839-45.
Hoppe RT, Fuks Z, Bagshaw MA. The rationale for curative radiotherapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 1977; 2: 843-51.
Campbell BA, Ryan G, McCormack C et al. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. Cancers (Basel) 2019; 11: 1758.
Specht L, Dabaja B, Illidge T et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 2015; 92: 32-9.
Kamstrup MR, Specht L, Skovgaard GL et al. A prospective, open-label study of low-dose total skin electron beam therapy in mycosis fungoides. Int. J. Radiat. Oncol. Biol. Phys. 2008; 71: 1204-7.
Harrison C, Young J, Navi D et al. Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int. J. Radiat. Oncol. Biol. Phys. 2011; 81: 651.
Huen AO, Kim EJ. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol. Clin. 2015; 33: 715-29.
Vonderheid EC. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Arch. Dermatol. 1987; 123: 757-63.
Kohn EC, Steis RG, Sausville EA et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome. J. Clin. Oncol. 1990; 8: 155-60.
Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am. 1995; 9: 1089-107.
Prince HMP, Bouthaina Dabaja B, Illidge T et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017; 390: 555-66.
Morris S, Scarisbrick J, Frew J et al. The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. Int. J. Radiat. Oncol. Biol. Phys. 2017; 99: 627-33.
Kamstrup MR, Lindahl LM, Gniadecki R et al. Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br. J. Dermatol 2012; 166: 399-404.
Hoppe RT, Harrison C, Tavallaee M et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J. Am. Acad. Dermatol. 2015; 72: 286-92.
Olsen E, Kim YH, Kuzel T et al. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial. J. Clin. Oncol. 2006; 24(18_suppl): 7500.
Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9.
Kim YH, Bagot M, Pinter-Brown L et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19: 1192-204.
Whittaker SJ, Demierre M-F, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Cin. Oncol. 2010; 28: 4485-91.
Duvic M, Bates SE, Piekarz R et al. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leukemia & Lymphoma 2018; 59: 880-7.
Thursky KA, Worth LJ, Seymour JF et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br. J. Haematol. 2006; 132: 3-12.
Wu PA, Kim YH, Lavori PW et al. A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Biol. Blood Marrow Transplant 2009; 15: 982-90.
Burt R, Guitart J, Traynor A et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant. 2000; 25: 111-3.
Sureda A, Zhang M-J, Dreger P et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Cancer 2018; 124: 1733-42.
Duarte RF, Boumendil A, Onida F et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis, in. J Clin Oncol. 2014:32; 3347-8.
Lechowicz MJ, Lazarus HM, Carreras J et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and sezary syndrome. Bone Marrow Transplant 2014; 49: 1360-5.
de Masson A, Beylot-Barry M, Bouaziz J-D et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica 2014; 99: 527-34.
Cudillo L, Cerretti R, Picardi A et al. Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. Ann Hematol 2018; 97: 1041-8.
Hosing C, Bassett R, Dabaja B et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann. Oncol. 2015; 26: 2490-5.
Ahlawat SEA. A multi-centre retrospective analysis of outcomes following allogeneic stem-cell transplant in patients with cutaneous T-cell lymphoma. 2019: T-cell Lymphoma Forum, La Jolla.
Gao C, McCormack C, van der Weyden C et al. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome. Blood 2019; 134: 1346-50.
Wilson LD Jones GW, Kim D et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J. Am. Acad. Dermatol. 2000; 43(1 Pt 1): 54-60.
Duvic M, Donato M, Dabaja B et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J. Clin. Oncol 2010; 28: 2365-72.
Querfeld C, Rosen ST, Guitart J et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood 2014; 123: 1159-66.
Khodadoust MS, Rook AH, Porcu P et al. Pembrolizumab in relapsed and refractory mycosis fungoides and sezary syndrome: a multicenter phase II study. J. Clin. Oncol. 2020; 38: 20-8.